patent/CN-105873910-A

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105873910-A

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e071d18fea054bf8d1420d483e78ed1
classificationCPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D259-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50
filingDate	2012-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a366d8cbce288c67a2419f1961c3cce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_590cc443536a933d9b471ea980a4a6ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3eee7d77f3c86cb4dc8ea5c7fab40e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59e7b8f45729709fb3d6fa2c94276337
publicationDate	2016-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	CN-105873910-A
titleOfInvention	Macrocyclic insulin-degrading enzyme (IDE) inhibitors and uses thereof
abstract	The present invention relates to macrocyclic compounds that specifically inhibit insulin degrading enzyme (IDE). The present invention also relates to pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, polymorphs, tautomers, isotopically enriched forms and prodrugs of macrocyclic IDE inhibitors. The present invention also relates to its pharmaceutical composition. The present invention also relates to methods of using IDE inhibitors and pharmaceutical compositions comprising IDE inhibitors in vivo and in vitro, for example, in subjects exhibiting abnormal IDE activity, impaired insulin signaling, or insulin resistance, for example, subjects with diabetes The method of suppressing the IDE among them.
priorityDate	2011-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008156701-A2
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466798288 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468129188 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466798289

Total number of triples: 33.